25 January 2010
Company Ranks No. 13 on FORTUNE'S 2010 "100 Best Companies to Work For' List
18 November 2009
Balloon Catheter from QXMédical complements GORE EXCLUDER® AAA Endoprosthesis for endovascular aortic repair
December 21, 2009
Integrated radial support offers all the benefits of a ringed graft while the GORE PROPATEN Bioactive Surface helps to improve thromboresistance and patency.
7 November 2009
First human implant highlights innovative, conformable design of GORE TAG Thoracic Endoprosthesis
20 October 2009
W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG® Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs)
17 September 2009
Physicians report new information at the Society for Vascular Surgery's annual meeting
21 July 2009
Improved design now available with lower profile delivery system for use in iliac arteries.
June 30, 2009
Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries
14 May 2009
Larger device sizing option allows physicians to deliver safe, effective and proven treatment to broader patient population
04 May 2009
Combines Proven Synthetic Bioabsorbable Material with a Patented Design Engineered to Optimize Operative Success
28 April 2009
Minimally invasive treatment now available to broader patient population
24 March 2009
Unique device design allows physicians to deliver safe, effective and proven treatment to broader patient population
18 March 2009
Multi-center, multi-year, worldwide data presented adds to the growing body of evidence for ePTFE Heparin Vascular Graft
10 March 2009
Breakthrough Gore system provides neuroprotection during carotid artery stenting by reversing blood flow at the treatment site
27 February 2009
Company Earns a Spot on Fast Company’s 2009 “Fast 50” List
17 February 2009
Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients
09 February 2009
Breakthrough system provides neuroprotection during carotid artery stenting by reversing blood flow at the treatment site and continuously directing emboli away from the brain
08 February 2009
With more than 30,000 devices distributed worldwide, the premiere choice for the treatment of TAA is now available with an improved catheter delivery system
22 January 2009
Company Earns #15 Position on FORTUNE’S 2009 “100 Best Companies to Work For” List
16 January 2009
Multi-center study will evaluate safety and efficacy of the GORE Embolic Filter in carotid stenting for high risk surgical patients
09 January 2009
Gore’s proprietary heparin surface has proven valuable in the clinical treatment of arterial vascular disease.
12 December 2008
Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
29 October 2008
W. L. Gore & Associates, Inc. has been sued by NMT Medical, Inc. and Dr. Lloyd Marks in the United States (U.S.) District Court for the District of Delaware for allegedly infringing U.S. Patent 5,108,420 ('420 Patent) through the manufacture and sale of its GORE HELEX Septal Occluder devices.
16 October 2008
Study reports low major adverse event rates using the GORE Flow Reversal System
10 October 2008
Multi-center study will evaluate the safety and efficacy of the GORE Embolic Filter in conjunction with FDA-approved carotid stents
08 October 2008
Gore continues commitment to clinical research with symposia, ongoing clinical studies and emerging technologies
01 October 2008
First and only 100% monofilament PTFE, large-pore knitted surgical mesh designed for long-term patient comfort and quality of life
17 September 2008
IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)
17 September 2008
Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries
22 July 2008
Interim and pivotal data presented at Society of Vascular Surgery’s Annual Meeting
15 June 2008
Gore adds thinner, more flexible, custom size bioabsorbable product.
07 June 2008
More than 2,500 colorectal implants of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement for circular surgical staplers in past year
04 June 2008
Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms
06 May 2008
Distinguished seal allows biomaterial to be used across the European Union
05 May 2008
Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management
29 April 2008
W. L. Gore & Associates announced the availability of a new GORE-TEX® Suture compatible with the CAPIO® CL Transvaginal, Open Access and Standard Suture Capturing Devices from Boston Scientific.
09 April 2008
W. L. Gore & Associates (Gore) today announced the availability of GORE BIO-A Tissue Reinforcement, a synthetic matrix material that encourages tissue generation in soft tissue reinforcement applications.
07 April 2008
The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.
24 March 2008
Post-market study to compare performance of GORE PROPATEN Vascular Graft todisadvantaged autologous vein graft in below-knee peripheral arterial disease bypasses.
25 February 2008
Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.
24 January 2008
W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on FORTUNE magazine’s annual list of the “100 Best Companies to Work For” for the 11th consecutive year.
01 January 2008
Company Founded in Family Basement Now Global Enterprise
02 January 2008
Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease
11 December 2007
W. L. Gore & Associates (Gore) announced that interim results from multi-year, multi-center studies using the GORE PROPATEN Vascular Graft were presented recently at the 34th Annual VEITHsymposium™ in New York.
12 November 2007
On Dec 5, 2007, at 3 pm (CT) Zvonimir Krajcer, MD, FACC, Co-Director- Peripheral Vascular Intervention and Clinical Professor of Medicine at Baylor College of Medicine will perform an endovascular abdominal aortic aneurysm (AAA) repair with the GORE EXCLUDER® AAA Endoprosthesis at St. Luke’s Episcopal Hospital and Texas Heart Institute in Houston,Texas.
26 October 2007
On Nov 14th, 2007, at 9 am (PST) the vascular surgery team at Kaiser Permanente Fontana Hospital, consisting of Paul Aka, MD, FACS, Jeffrey Hsu, MD, Majid Tayyarah, MD and Trung Vo, MD, will perform an endovascular abdominal aortic aneurysm (AAA) repair through a percutaneous approach with the GORE EXCLUDER® AAA Endoprosthesis.
27 October 2007
Heart Disease: On Nov 16th, 2007, see a live endovascular repair of a descending thoracic aortic aneurysm with the GORE TAG® Thoracic Endoprosthesis. Michael D. Dake, MD, Professor of Radiology, Internal Medicine, Surgery and Chairman of the UVA Department of Radiology will host this live broadcast.
25 October 2007
On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.
18 October 2007
The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.
11 October 2007
W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).
03 October 2007
W. L. Gore & Associates today announced that the US Food & Drug Administration (FDA) granted approval for the GORE HELEX Septal Occluder with modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD).
05 September 2007
Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions
03 August 2007
W. L. Gore & Associates (Gore) announced that it will expand its Medical Products Division’s operations in Arizona after completing the purchase today of approximately 40 acres of land in North Phoenix.
13 July 2007
Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.
29 June 2007
Next in educational series planned for July 12-13, 2007 in Chicago
W. L. Gore & Associates, Inc. is conducting a series of regional advanced AAA symposia throughout the year.
22 May 2007
Preliminary data shows a statistically significant reduction in anastomotic stricture rate and trends toward decreased anastomotic bleeding and leak rates.
07 May 2007
W. L. Gore & Associates (Gore) announced today the availability of GORE PRECLUDE® Vessel Guard, the first non-biological membrane indicated as a cover for vessels following anterior vertebral surgery.
07 May 2007
Sponsored by Gore, the VIBRANT Study is a randomized, prospective, multi-center clinical trial intended to demonstrate mid- and long-term superior performance in the treatment of SFA lesions eight centimeters or longer with the GORE VIABAHN® Endoprosthesis compared to bare nitinol stents.
19 April 2007
On May 17, 2007, at 4 pm (EST) Mark A. Adelman, MD, FACS, Associate Professor of Surgery and Chief, Division of Vascular Surgery at NYU Medical Center will perform an endovascular abdominal aortic aneurysm (AAA) repair with the GORE EXCLUDER® AAA Endoprosthesis.
21 February 2007
W. L. Gore & Associates, Inc announced today expansion plans for its Arizona medical products operations to meet anticipated growth.
20 February 2007
W. L. Gore & Associates announced today that the first patient has been enrolled in a US Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta.
14 February 2007
Hernia repair patch is the only to inhibit adherence of 10 different bacteria and resist initial biofilm formation for 14 days post-implantation
12 February 2007
Gore joins with the Society for Vascular Surgery (SVS) to urge the public to make the “Ultimate SAAAVE” by getting screened for AAA
02 Feburary 2007
Surgeons at Baylor Heart and Vascular Hospital in Dallas, Texas will perform a minimally invasive descending thoracic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis that will be webcast on March 1, 2007 at 4 pm CST.
30 Janaury 2007
W. L. Gore & Associates has received regulatory clearance on January 22, 2007 from the Pharmaceuticals and Medical Device Agency to market its GORE EXCLUDER® AAA Endoprosthesis in Japan.
08 January 2007
W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on FORTUNE magazine’s annual list of the “100 Best Companies to Work For” for the 10th consecutive year.